[go: up one dir, main page]

AU2024273592A1 - Methods and compositions for reducing antibody viscosity - Google Patents

Methods and compositions for reducing antibody viscosity

Info

Publication number
AU2024273592A1
AU2024273592A1 AU2024273592A AU2024273592A AU2024273592A1 AU 2024273592 A1 AU2024273592 A1 AU 2024273592A1 AU 2024273592 A AU2024273592 A AU 2024273592A AU 2024273592 A AU2024273592 A AU 2024273592A AU 2024273592 A1 AU2024273592 A1 AU 2024273592A1
Authority
AU
Australia
Prior art keywords
compositions
methods
reducing antibody
viscosity
antibody viscosity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2024273592A
Inventor
Paul John Carter
Jing Dai
Saeed IZADI
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genentech Inc
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of AU2024273592A1 publication Critical patent/AU2024273592A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2869—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against hormone receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Epidemiology (AREA)
  • Veterinary Medicine (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Mycology (AREA)
  • Analytical Chemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
AU2024273592A 2023-05-12 2024-05-10 Methods and compositions for reducing antibody viscosity Pending AU2024273592A1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202363466219P 2023-05-12 2023-05-12
US63/466,219 2023-05-12
US202363587649P 2023-10-03 2023-10-03
US63/587,649 2023-10-03
PCT/US2024/028793 WO2024238332A1 (en) 2023-05-12 2024-05-10 Methods and compositions for reducing antibody viscosity

Publications (1)

Publication Number Publication Date
AU2024273592A1 true AU2024273592A1 (en) 2025-11-20

Family

ID=91586175

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2024273592A Pending AU2024273592A1 (en) 2023-05-12 2024-05-10 Methods and compositions for reducing antibody viscosity

Country Status (5)

Country Link
CN (1) CN121079327A (en)
AU (1) AU2024273592A1 (en)
MX (1) MX2025013491A (en)
TW (1) TW202448509A (en)
WO (1) WO2024238332A1 (en)

Family Cites Families (53)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE30985E (en) 1978-01-01 1982-06-29 Serum-free cell culture media
US4560655A (en) 1982-12-16 1985-12-24 Immunex Corporation Serum-free cell culture medium and process for making same
US4657866A (en) 1982-12-21 1987-04-14 Sudhir Kumar Serum-free, synthetic, completely chemically defined tissue culture media
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4767704A (en) 1983-10-07 1988-08-30 Columbia University In The City Of New York Protein-free culture medium
AU4434585A (en) 1985-03-30 1986-10-23 Marc Ballivet Method for obtaining dna, rna, peptides, polypeptides or proteins by means of a dna recombinant technique
GB8516415D0 (en) 1985-06-28 1985-07-31 Celltech Ltd Culture of animal cells
US4927762A (en) 1986-04-01 1990-05-22 Cell Enterprises, Inc. Cell culture medium with antioxidant
US5763192A (en) 1986-11-20 1998-06-09 Ixsys, Incorporated Process for obtaining DNA, RNA, peptides, polypeptides, or protein, by recombinant DNA technique
US5266684A (en) 1988-05-02 1993-11-30 The Reagents Of The University Of California Peptide mixtures
US5571689A (en) 1988-06-16 1996-11-05 Washington University Method of N-acylating peptide and proteins with diheteroatom substituted analogs of myristic acid
US5663143A (en) 1988-09-02 1997-09-02 Dyax Corp. Engineered human-derived kunitz domains that inhibit human neutrophil elastase
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
DE68925971T2 (en) 1988-09-23 1996-09-05 Cetus Oncology Corp CELL GROWING MEDIUM FOR INCREASED CELL GROWTH, FOR INCREASING LONGEVITY AND EXPRESSION OF PRODUCTS
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
AU638762B2 (en) 1989-10-05 1993-07-08 Optein Inc Cell-free synthesis and isolation of novel genes and polypeptides
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
ATE139258T1 (en) 1990-01-12 1996-06-15 Cell Genesys Inc GENERATION OF XENOGENE ANTIBODIES
US5498538A (en) 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
US5723286A (en) 1990-06-20 1998-03-03 Affymax Technologies N.V. Peptide library and screening systems
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
AU8507191A (en) 1990-08-29 1992-03-30 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5770434A (en) 1990-09-28 1998-06-23 Ixsys Incorporated Soluble peptides having constrained, secondary conformation in solution and method of making same
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
US5122469A (en) 1990-10-03 1992-06-16 Genentech, Inc. Method for culturing Chinese hamster ovary cells to improve production of recombinant proteins
US5270170A (en) 1991-10-16 1993-12-14 Affymax Technologies N.V. Peptide library and screening method
US5627024A (en) 1994-08-05 1997-05-06 The Scripps Research Institute Lambdoid bacteriophage vectors for expression and display of foreign proteins
EP0822830B1 (en) 1995-04-27 2008-04-02 Amgen Fremont Inc. Human anti-IL-8 antibodies, derived from immunized xenomice
EP0823941A4 (en) 1995-04-28 2001-09-19 Abgenix Inc Human antibodies derived from immunized xenomice
JPH11507246A (en) 1996-03-20 1999-06-29 ダイアックス コープ． Designing affinity ligands for macromolecules
EP0954531A1 (en) 1996-06-06 1999-11-10 Lajolla Pharmaceutical Company aPL IMMUNOREACTIVE PEPTIDES, CONJUGATES THEREOF AND METHODS OF TREATMENT FOR aPL ANTIBODY-MEDIATED PATHOLOGIES
DE69731226T2 (en) 1996-06-10 2006-03-09 The Scripps Research Institute, La Jolla USE OF SUBSTRATE SUBTRACTION LIBRARIES FOR THE DISTINCTION OF ENZYME SPECIFICATIONS
US5766905A (en) 1996-06-14 1998-06-16 Associated Universities Inc. Cytoplasmic bacteriophage display system
WO1998014277A1 (en) 1996-10-04 1998-04-09 Whatman, Inc. Device and method for simultaneous multiple chemical syntheses
DK0934526T3 (en) 1996-10-08 2003-05-05 Bisys B V U Methods and means for selecting peptides and proteins that have specific affinity for a target
IL129772A0 (en) 1996-11-06 2000-02-29 Genentech Inc Constrained helical peptides and methods of making same
IL119587A (en) 1996-11-07 2000-12-06 Univ Ramot Method of preparing and for obtaining bimolecular interactions
IL119586A (en) 1996-11-07 2001-09-13 Univ Ramot Discontinuous library of a single biological unit and a method for its preparation
EP1500329B1 (en) 1996-12-03 2012-03-21 Amgen Fremont Inc. Human antibodies that specifically bind human TNF alpha
KR100566859B1 (en) 1997-01-21 2006-04-03 제너럴 하스피톨 코포레이션 Screening for Proteins Using the RNA-Protein Fusion
US6261804B1 (en) 1997-01-21 2001-07-17 The General Hospital Corporation Selection of proteins using RNA-protein fusions
ES2280131T3 (en) 1998-12-02 2007-09-01 Adnexus Therapeutics, Inc. DNA-PROTEIN FUSIONS AND USES OF THE SAME.
EP1930342B1 (en) 2006-12-04 2012-01-25 Institut Pasteur OB-fold used as scaffold for engineering new specific binders
AU2010282508B2 (en) 2009-08-13 2015-05-28 Crystal Bioscience Inc. Transgenic animal for production of antibodies having minimal CDRs
AU2012258786B2 (en) 2011-05-24 2017-02-02 Crystal Bioscience Inc. Transgenic chicken comprising an inactivated immunoglobulin gene
WO2013059531A1 (en) 2011-10-20 2013-04-25 Genentech, Inc. Anti-gcgr antibodies and uses thereof
US9394372B2 (en) 2011-10-21 2016-07-19 Crystal Bioscience Inc. In vivo method for generating diversity in a protein scaffold
WO2023053891A1 (en) * 2021-09-29 2023-04-06 富士フイルム株式会社 Pharmaceutical assistance device, operation method for pharmaceutical assistance device, and operation program for pharmaceutical assistance device

Also Published As

Publication number Publication date
CN121079327A (en) 2025-12-05
WO2024238332A1 (en) 2024-11-21
MX2025013491A (en) 2025-12-01
TW202448509A (en) 2024-12-16

Similar Documents

Publication Publication Date Title
CA3260121A1 (en) Anti-gal3 antibodies and compositions
EP4149450A4 (en) Compositions and methods for hardening
EP4206233A4 (en) Emulsion composition and method for producing same
AU2024273592A1 (en) Methods and compositions for reducing antibody viscosity
CA3290650A1 (en) Methods and compositions for reducing antibody viscosity
CA3260587A1 (en) Fah-modulating compositions and methods
CA3257995A1 (en) Anti-cd20 antibody compositions
EP4126900A4 (en) Composition and method
EP4100122A4 (en) Composition and method
CA3281693A1 (en) Compositions and methods for anti-pacap igg4 antibodies
HK40111253A (en) Compositions and methods for anti-pacap antibodies
EP4247965A4 (en) Methods and assays for analyzing secretome-containing compositions
HK40104694A (en) Compositions and methods for anti-pacap antibodies
AU2024259472A1 (en) Compositions and methods for immunotherapy - ii
CA3272252A1 (en) Anti-ctla antibody compositions and related methods
HK40106092A (en) Anti-nkg2a antibodies and compositions
CA3286507A1 (en) Compositions and methods for agri-inputs and uses thereof
HK40117236A (en) Compositions and methods comprising anti-nrp2a antibodies
HK40107746A (en) Antibody composition
CA3257865A1 (en) Composition and method
HK40059110B (en) Composition and method
HK40107098A (en) Antibody composition
HK40119431A (en) Stable antibody composition
AU2022900795A0 (en) Cannabis oil compositions and methods for preparation thereof
AU2021401712A9 (en) Antibody composition